Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19738020 | 0.77 | ALDH1A1 (0.35) | P2RX7ALDH1A1MAPK1POLBGRM5 | |
| SCHEMBL24656057 | 0.77 | PIK3CA (0.33) | ALDH1A1POLBGRM5MAP4K1NPC1 | |
| SCHEMBL2955619 | 0.73 | ALDH1A1 (0.32) | ALDH1A1POLBGRM5 | |
| SCHEMBL23707053 | 0.73 | CPB2 (0.39) | ALDH1A1POLBTSHRGRM5MAP4K1 | |
| SCHEMBL25423071 | 0.73 | — | — | |
| SCHEMBL20370769 | 0.73 | ALDH1A1 (0.32) | ALDH1A1POLBMAP4K1LMNA | |
| SCHEMBL21532830 | 0.73 | LMNA (0.32) | ALDH1A1POLBMAP4K1TP53MAPT | |
| SCHEMBL18365809 | 0.72 | POLB (0.41) | ALDH1A1MAPK1POLBTSHRNPC1 | |
| SCHEMBL599822 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL21818893 | 0.70 | POLB (0.41) | ALDH1A1MAPK1POLBTSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577536-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | Hotspot Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | DRAIG THERAPEUTICS LTD (GB) | 2024-12-26 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4334301-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | University College Cardiff Consultants Limited (GB) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044344-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044344-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| WO-2021050964-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| US-10196385-B2 | Tetrahydropyranyl benzamide derivatives | ELI LILLY AND COMPANY (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196385-B2 | Tetrahydropyranyl benzamide derivatives | ELI LILLY AND COMPANY (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180194755-A1 | Tetrahydropyranyl Benzamide Derivatives | ELI LILLY AND COMPANY | 2018-07-12 | — | — | US | disclosed |
| US-20180194755-A1 | Tetrahydropyranyl Benzamide Derivatives | ELI LILLY AND COMPANY | 2018-07-12 | — | — | US | disclosed |
| US-20180194755-A1 | Tetrahydropyranyl Benzamide Derivatives | ELI LILLY AND COMPANY | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196385-B2 | Tetrahydropyranyl benzamide derivatives | INSR, GPR119, GLP1R | P2RX7 2077/4885ALDH1A1 1062/4885MAPK1 3655/4885 |
| US-20210078998-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | P2RX7 1379/4885ALDH1A1 4044/4885MAPK1 526/4885 |
| US-20180194755-A1 | Tetrahydropyranyl Benzamide Derivatives | INSR, GPR119, GLP1R | P2RX7 2040/4885ALDH1A1 958/4885MAPK1 4099/4885 |
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | P2RX7 2004/4885ALDH1A1 3268/4885MAPK1 564/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | P2RX7 3035/4885ALDH1A1 4164/4885MAPK1 1799/4885 |
| US-20240150365-A1 | PYRIDINYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | P2RX7 1945/4885ALDH1A1 3059/4885MAPK1 375/4885 |
| US-20240425491-A1 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | GABRA5, GABRB3, GABRA3 | P2RX7 428/4885ALDH1A1 1189/4885MAPK1 3891/4885 |
| US-20210087190-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | P2RX7 1379/4885ALDH1A1 4044/4885MAPK1 526/4885 |
| US-20210078997-A1 | SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS | HIPK1, PDXK, IP6K1 | P2RX7 1591/4885ALDH1A1 3749/4885MAPK1 535/4885 |
| US-20210078996-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | P2RX7 2163/4885ALDH1A1 4740/4885MAPK1 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.